

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|--|
| USAN (AB-28) | CAPLACIZUMAB |
| PRONUNCIATION | kap" la siz' ue mab |
| THERAPEUTIC CLAIM | Treatment of thrombotic thrombocytopenic purpura, thrombosis |
| CHEMICAL NAMES | |

1. Immunoglobulin, anti-(human von Willebrand's blood-coagulation factor VIII domain A1) (human-*Lama glama* dimeric heavy chain fragment PMP12A2h1)
2. Immunoglobulin VH-linker-VH fragment, anti-[*Homo sapiens* VWF (von Willebrand factor) A1 domain], humanized monoclonal antibody; VH-linker-VH chain (1,259) [humanized VH (*Homo sapiens* IGHV3-23*04 (82.5%) –(IGHD)-IGHJ4*01 L123>Q(123) [8.8.21] (1-128)]-trialanyl linker (129-131)-[humanized VH (*Homo sapiens* IGHV3-23*04 (82.5%) –(IGHD)-IGHJ4*01 L123>Q(254) [8.8.21] (132-259)]

STRUCTURAL FORMULA

Single chain sequence

| | | | | | |
|------------|------------|------------|------------|------------|-----|
| EVQLVESGGG | LVQPGGSLRL | SCAASGRFTS | YNPMGWFRQA | PGKGRELVA | 50 |
| ISRTGGSTYY | PDSVEGRFTI | SRDNAKRMVY | LQMNSLRAED | TAVYYCAAAG | 100 |
| VRAEDGRVRT | LPSEYTFWQ | GTQVTVSSAA | AEVQLVESGG | GLVQPGGSLR | 150 |
| LSCAASGRTF | YNPMGWFRQ | APKGRELVA | AISRTGGSTY | YPDSVEGRFT | 200 |
| ISRDNAKRMV | YLQMNSLRAE | DTAVYYCAA | GVRAEDGRVR | TLPSEYTFWG | 250 |
| QGTQVTVSS | | | | | 300 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 153-227

| | |
|----------------------------|--|
| MOLECULAR FORMULA | $C_{1213}H_{1891}N_{357}O_{380}S_{10}$ |
| MOLECULAR WEIGHT | 27.88 kDa |
| TRADEMARK | None as yet |
| SPONSOR | Ablynx NV |
| CODE DESIGNATIONS | ALX-0081 |
| <u>CAS</u> REGISTRY NUMBER | 915810-67-2 |
| WHO NUMBER | 9511 |

gbk